Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.
Ranking research peptides by scientific utility requires considering three factors: published study volume (how extensively has the mechanism been characterized?), research versatility (how many distinct tissue types and endpoints has it been applied to?), and current research momentum (is the field actively expanding?). This ranking reflects the research landscape as of 2025, with each compound scored across these dimensions.
#1 — BPC-157 (Body Protection Compound-157)#
Study count: 100+ published studies (Medline indexed) Primary targets: VEGF/Egr-1 angiogenesis axis, eNOS/NO signaling, COX-2 modulation Research versatility: Tendon, muscle, bone, gut, CNS, cardiovascular, cornea
BPC-157 leads all synthetic research peptides on published study volume. The 15-amino acid sequence (GEPPPGKPADDAGLV) derived from human gastric juice protein has been studied in tendon repair, muscle repair, bone repair, gastric ulcer, gut motility, inflammatory bowel models, traumatic brain injury, and corneal wound healing — spanning more tissue types than any comparable synthetic peptide.
Why #1: Mechanistic depth (multi-pathway rather than single target), reproducibility across independent laboratories, well-characterized VEGF→angiogenesis primary mechanism, and continued active research program (Sikiric group publishing through 2024–2025).
Current research questions: Oral vs. SC bioavailability; systemic vs. local delivery in non-GI tissues; human-equivalent dosing translation; combination with TB-500 for repair synergy.
#2 — Semaglutide#
Study count: 1,000+ indexed studies (pharma-sponsored + independent) Primary targets: GLP-1 receptor (pancreatic, hypothalamic, vagal, hepatic) Research versatility: Metabolic (obesity, T2DM), cardiovascular, NASH, neurodegeneration
Semaglutide's total indexed study count exceeds any other compound on this list by orders of magnitude — a consequence of Phase 2/3 clinical trial programs. In preclinical research, it remains the GLP-1R agonist reference compound: every new GLP-1 mechanism study uses semaglutide as a comparator. DIO C57BL/6J mouse protocols using semaglutide are the best-characterized model for metabolic compound research.
Why #2: Ubiquitous use as the GLP-1R standard makes semaglutide research findings the most immediately comparable to clinical literature.
#3 — Ipamorelin#
Study count: 50+ indexed studies Primary targets: GHSR-1a (ghrelin receptor) Research versatility: GH axis, body composition, gut motility (post-operative ileus), anti-inflammatory
Ipamorelin is the most selective GHSR-1a agonist in the research toolkit — it produces clean GH pulses without the cortisol, prolactin, or appetite stimulation that confound GHRP-2 and GHRP-6 research. This selectivity makes ipamorelin the preferred compound when studying the GH/IGF-1 axis without hormonal interference.
Current 2025 research momentum: Post-operative ileus research (ipamorelin's pro-motility effects independent of GH axis); combination with CJC-1295 for supra-additive GH release; longevity research (somatopause reversal in aged animal models).
#4 — TB-500 (Thymosin Beta-4 Analog)#
Study count: 80+ studies on thymosin beta-4 (the parent peptide); TB-500 is the synthetic research form Primary targets: G-actin sequestration (Tβ4-Ac-SDKP domain), VEGF upregulation, cell migration Research versatility: Cardiac, skeletal muscle, tendon, cornea, CNS
TB-500's research history is longer than BPC-157's (thymosin beta-4 was isolated in 1965), but the synthetic form (TB-500) has a narrower focused research program. The cardiac research is particularly compelling: thymosin beta-4 was shown to activate cardiac progenitor cells in adult myocardium — a finding with potential implications for post-infarction repair research.
Research highlight 2024–2025: TB-500's LKKTET domain (different from BPC-157's VEGF-driven mechanism) for cardiac repair research; combination BPC-157+TB-500 stacks for complementary angiogenic mechanisms.
#5 — Retatrutide#
Study count: 50+ studies (primarily from Phase 2 clinical program and DIO model preclinical) Primary targets: GLP-1R + GIPR + GCGR (triple agonist) Research versatility: Obesity, T2DM, NASH, cardiovascular, lean mass preservation
Retatrutide is the highest-momentum compound on this list — Phase 2 data showing 24% body weight loss at 48 weeks is the highest efficacy of any pharmacological compound studied for obesity. The triple agonism (adding glucagon receptor to GLP-1/GIP dual agonism) increases energy expenditure while reducing intake — a unique metabolic profile.
Research momentum: Every mechanism question from dual agonism (tirzepatide) must be re-asked for triple agonism. 2025 is the peak year for retatrutide DIO model mechanistic research.
Retatrutide, €75 · 98.5% purity#6 — CJC-1295#
Study count: 40+ indexed studies Primary targets: GHRHR (growth hormone-releasing hormone receptor) Research versatility: GH pulse frequency/amplitude modulation; body composition; bone density; GH axis synergy with GHSR-1a agonists
CJC-1295 (with or without DAC) occupies the GHRHR position in the GH axis toolkit — it extends GH pulse duration rather than triggering discrete pulses. The CJC-1295 + ipamorelin combination (GHRHR + GHSR-1a) produces supra-additive GH release through two independent signaling pathways (Gαs/cAMP and Gαq/Ca²⁺) — the most studied GH secretagogue combination in research.
2025 research focus: CJC-1295 with DAC (MOD GRF long-acting) vs. without DAC for maintaining physiological GH pulsatility vs. sustained elevation; comparison with MK-677 for oral GH axis research.
#7 — SS-31 (Elamipretide)#
Study count: 60+ indexed studies Primary targets: Cardiolipin (mitochondrial inner membrane) Research versatility: Heart failure, aged skeletal muscle, retinal degeneration, kidney disease, neurodegeneration
SS-31's mechanism — direct cardiolipin interaction preserving cristae architecture and ETC supercomplex stability — is uniquely targeted. No other research peptide addresses the mitochondrial structural problem directly. Elamipretide is in clinical trials for Barth syndrome (cardiolipin synthesis defect) and heart failure — clinical validation of the mitochondrial cardiolipin hypothesis.
Why #7: Mechanistic uniqueness (no overlap with other compounds), growing evidence across multiple organ systems, and clinical trial progress providing translational context.
#8 — Tirzepatide#
Study count: 300+ indexed studies (clinical program + preclinical) Primary targets: GLP-1R + GIPR (dual agonist) Research versatility: Obesity, T2DM, NASH, cardiovascular, β-cell preservation
Tirzepatide bridged the gap between mono-agonism (semaglutide) and triple agonism (retatrutide). SURMOUNT-1 data (22.5% weight loss) established dual agonism's superiority. Current research focus: teasing apart GLP-1R vs. GIPR contributions to the compound's effects — difficult because the two receptors share downstream signaling overlap.
#9 — PT-141 (Bremelanotide)#
Study count: 40+ indexed studies Primary targets: MC3R and MC4R (melanocortin receptors 3 and 4) Research versatility: Sexual function (CNS-mediated arousal), melanocortin system, appetite regulation, inflammation
PT-141's distinctive mechanism — central CNS-mediated melanocortin pathway activation (MC3R/MC4R in hypothalamic circuits) rather than PDE5 inhibition at the vascular level — makes it uniquely informative for studying the neurobiological substrates of sexual behavior and arousal. It is FDA-approved (Vyleesi) for hypoactive sexual desire disorder, providing clinical validation of the MC4R mechanism.
Research applications beyond sexual function: MC4R's role in energy homeostasis (melanocortin tone is a major appetite regulator); MC3R in immune modulation; alpha-MSH cascade in inflammatory disease models.
#10 — NAD+ Precursors (NMN / NR)#
Study count: 200+ studies on NAD+ precursors combined Primary targets: NAD+ / SIRT1 / SIRT3 / PARP / CD38 Research versatility: Aging, metabolic disease, neurodegeneration, DNA repair, mitochondrial function
Strictly speaking, NMN and NR are precursor molecules rather than peptides — but the NAD+ research area is too significant to exclude from a 2025 "most important research compound" list. The mechanistic hypothesis (age-related NAD+ decline → sirtuin inactivation → accelerated aging hallmarks) is actively being tested in aged animal models, with human longevity trials underway.
Research consideration: NMN vs. NR bioavailability controversy (whether NMN is cleaved to NR before intestinal absorption, or absorbed directly); tissue-specific NAD+ elevation; CD38 inhibition as a complementary strategy.
Research Use Only. JuicedPharma does not provide medical advice.
Published by JuicedPharma Research Team · October 2026 · Category: Research Protocols & Science
